Clinical Trials Logo

PD-1 Inhibitors clinical trials

View clinical trials related to PD-1 Inhibitors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05520814 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1 inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainties about the timing, fraction dose and total dose for PD-1 inhibitors combination with radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new pattern for R/M NPC.